Evaluation of utility index of quality of life (QOL) in prostate cancer patients: Comparison of QOL utility index EuroQol-5D (Eq-5D) and visual analogue scale (Vas) with health-related QOL questionnaires Sf-36 and EPIC

Japanese Journal of Urology

Volumn 102, Issue 1, 2011, Pages 9-13

  Akakura, Koichiro ^a   Matsuzaki, Kanako ^a   Kobayashi, Takashi ^a   Kitoh, Hiroki ^a   Mizoguchi, Ken Ichi ^a   Tomikawa, Grace ^a   Takura, Tomoyuki ^b   Kawabuchi, Koichi ^c  

^a TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cost effectiveness analysis; Prostate cancer; Qaly (quality adjusted life year)

Indexed keywords

EID: 79952080732     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol.102.9     Document Type: Article

References (17)

1. Peeters A., Grutters J.P., Pijls-Johannesma M., Reimoser S., De Ruysscher D., Severens J.L., Joore M.A. and Lambin P.: How costly is particle therapy? Cost analysis of external beam radiotherapy with carbonions, protons and photons. Radiother. Oncol., 95, 45-53, 2010.
2. Siegel J.E., Torrance G.W., Russell L.B., Luce B.R., Weinstein M.C. and Gold M.R.: Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Pharmacoeconomics, 11, 159-168, 1997.
3. EuroQol Group: EuroQol; a new facility for the measurement of health-related quality of life. Health Policy, 16, 199-206. 1990.
4. Ware J. E.: The MOS 36-Item Short-Form Health Survey (SF-36) I. Conceptual framework and item selection. Med. Care, 30, 473-483, 1992.
5. Fukuhara S., Bito S., Green J., Hsiao A. and Kurosawa K.: Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J. Clin. Epidemiol., 51, 1037-1044, 1998.
6. Sanda M.G., Expanded Prostate Cancer Index Composite (EPIC) 96, 657-669, 2005.
7. Shmueli A.: The relationship between the visual analog scale and the SF-36 scales in the general population: an update. Med. Decis. Making, 24, 61-63, 2004.
8. König H.H., Born A., Matschinger H., Heinrich S., Riedel-Heller S.G., Angermeyer M.C. and Roick C.: Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health Qual. Life Outcomes, 8, 47, 2010.
9. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B. and de Haes J.C.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst., 85, 365-376, 1993.
10. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., Silberman M., Yellen S.B., Winicour P. and Brannon J.: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol., 11, 570-579, 1993.
11. Esper P., Mo F., Chodak G., Sinner M., Cella D. and Pienta K.J.: Measuring quality of life in men with prostate cancer using Functional Assessment of Cancer Therapy-Prostate instrument Urology, 50, 920-928, 1997.
12. Litwin M.S., Hays R.D., Fink A., Ganz P.A., Leake B. and Brook R.H.: The UCLA Prostate Cancer Index: development, reliability, and validity of a healthrelated quality of life measure. Med. Care, 36, 1002-1012, 1998.
13. Wei J.T., Dunn R.L., Litwin M.S., Sandler H.M. and Sanda M.G.: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology, 56, 899-905, 2000.